Ionis (IONS) Director Ludwig Receives 3,399-Unit RSU Award

What Happened

• Ludwig Hantson, a director of Ionis Pharmaceuticals (IONS), received an award of 3,399 Restricted Stock Units (RSUs) on July 15, 2026. The grant was reported as a derivative acquisition (code A) at $0.00 per unit (no cash exchanged at grant). The RSUs represent contingent rights to receive one share of Ionis common stock (or cash equivalent) upon vesting.

Key Details

• Transaction date: July 15, 2026; filing date: July 17, 2026 (timely filing).
• Award: 3,399 RSUs granted under the Ionis Amended & Restated 2002 Non-Employee Directors' Stock Option Plan.
• Vesting: Three equal annual installments; first vesting on July 15, 2027; fully vested on July 15, 2029. RSUs vested as to 0 shares on the grant date.
• Price/value at grant: $0.00 recorded (no immediate cash purchase). Actual value will depend on Ionis share price at payout/vesting.
• Shares owned after transaction: Not specified in this filing.
• Footnote: RSUs may be settled in whole shares or cash as determined by the company.

Context

• This is a standard director compensation award (not an open-market purchase or sale). RSUs are a deferred/contingent form of compensation and do not represent immediately transferable shares until they vest.